GAP-486
Phase 2Small molecule
PfizerGAP-486 is one of 57 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
223 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsPhase 3
Leqvio
NovartisPhase 3
Vanrafia
NovartisPhase 3
Zetia
OOrganon and Co
Phase 3
Tekturna
Tibotec Pharmaceuticals, IrelandPhase 3
Kynamro
KKastle Therapeutics, LLC
Phase 3
Glutamine
SanofiPhase 3
Quercetin
MMayo Clinic
Phase 3
Praluent
RegeneronPreclinical
Repatha
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GAP-486. EMBL-EBI & Wellcome Sanger Institute.
- [4]